NIH/NIDA – Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01 Clinical Trial Optional)

March 16, 2018 by School of Medicine Webmaster

This FOA seeks to attract exceptionally talented investigators to conduct innovative, potentially groundbreaking and/or unconventional investigations on HIV/AIDS and substance abuse.  Projects may be led by collaborative investigative teams or individual scientists.  Awards will support projects, which, if successful, will have a major impact on HIV/AIDS and substance abuse. Examples of studies of relevance to drug abuse include: studies using populations with significant numbers of drug users or samples from drug using populations; studies using in vitro systems and/or animal models that test the effects of drugs of abuse on HIV pathogenesis, progression, or treatment; studies to develop interventions or treatments that are tailored to substance using populations, and studies of novel implementation approaches.  Projects may be in any area of research but must be in an area of high priority NIH HIV/AIDS research While not limited to any one area of research on HIV and substance use, this award is well-suited to conducting translational studies.  However, studies are not required to include a translational element.  This FOA is designed to complement NIDA’s existing Avant-Garde Award Program for HIV/AIDS Research and Avenir Award Program for Research on Substance Abuse and HIV/AIDS, which focus on individual researchers and which do not require a detailed research plan.  In contrast, this FOA focuses on innovative research projects, and applications to this FOA are expected to have a detailed research plan and preliminary data.  However, applications submitted under this FOA should clearly exhibit creativity, innovativeness, and risk.

Special Considerations

National Advisory Council on Drug Abuse Recommended Guidelines for the Administration of Drugs to Human Subjects:  The National Advisory Council on Drug Abuse (NACDA) recognizes the importance of research involving the administration of drugs with abuse potential, and dependence or addiction liability, to human subjects.   Potential applicants are encouraged to obtain and review these recommendations of Council before submitting an application that will administer compounds to human subjects.  The guidelines are available on NIDA’s Web site at

Points to Consider Regarding Tobacco Industry Funding of NIDA Applicants: The National Advisory Council on Drug Abuse (NACDA) encourages NIDA and its grantees to consider the points it has set forth with regard to existing or prospective sponsored research agreements with tobacco companies or their related entities and the impact of acceptance of tobacco industry funding on NIDA’s credibility and reputation within the scientific community.  Please see ( for details.

Data Harmonization for Substance Abuse and Addiction via the PhenX Toolkit:  NIDA strongly encourages investigators involved in human-subject studies to employ a common set of tools and resources that will promote the collection of comparable data across studies and to do so by incorporating the measures from the Core and Specialty collections, which are available in the Substance Abuse and Addiction Collection of the PhenX Toolkit (  Please see NOT-DA-12-008 ( for further details.

Deadlines:  August 22, 2018; August 22, 2019, August 21, 2020 (letters of intent due 30 days before deadline)


Filed Under: Funding Opportunities